Nicoletta Colombo, MD, PhD, Director of Gynecologic Cancer Medical Treatments at the European Institute of Oncology, emphasizes the importance of molecular profiling for predicting the need for adjuvant therapies in endometrial cancer patients. Dr. Colombo says molecular profiling classifies patients into four molecular subtypes. For instance, patients with more advanced cancers who were previously thought to be high risk might carry POLE mutations, putting them in the low-risk category. Additionally, P53 mutations are associated with high risk endometrial cancers and require more aggressive treatments.